18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy

ConclusionWe studied in vivo18F-Fluciclovine uptake in human prostate cancer orthograft models following acute and chronic ADT.18F-Fluciclovine uptakes highlight tumour heterogeneity that may explain castration resistance and can be exploited as a clinical biomarker.
Source: EJNMMI Research - Category: Radiology Source Type: research